Sopharma AD (WSE:SPH)

Market Cap	2.06B
Revenue (ttm)	4.69B
Net Income (ttm)	170.75M
Shares Out	n/a
EPS (ttm)	1.03
PE Ratio	12.04
Forward PE	n/a
Dividend	0.36 (2.93%)
Ex-Dividend Date	Nov 7, 2024

Volume	214
Average Volume	151
Open	12.40
Previous Close	12.40
Day's Range	12.40 - 12.50
52-Week Range	11.40 - 14.40
Beta	-0.04
RSI	46.73
Earnings Date	Mar 31, 2025

About Sopharma AD

Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. It offers Carsil to treat liver disease; Tempalgin and Analgin, a painkiller; Tabex, drug used for smoking secession; Tribestan, drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin, used for diseases of the peripheral nervous system; Methylprednisolon, for severe allergies and life-threatening conditions; Vitamin C; Valeriana, used to reduce the stress; and medical devices...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 1933
• Employees: 5,599
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: SPH

Financial Performance

In 2024, Sopharma AD's revenue was 2.14 billion, an increase of 13.27% compared to the previous year's 1.89 billion. Earnings were 77.85 million, a decrease of -18.89%.

Financial numbers in BGN